Novo Nordisk Finalizes Akero Deal to Advance MASH Phase 3 Therapy
Bagsværd, Denmark & South San Francisco, CA — December 9, 2025 — Novo Nordisk has officially completed its acquisition...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Bagsværd, Denmark & South San Francisco, CA — December 9, 2025 — Novo Nordisk has officially completed its acquisition...
AUSTIN, Texas — December 5, 2025 — Natera has announced the acquisition of Foresight Diagnostics, a precision oncology company...
New York, October 30, 2025 — Pfizer Inc. (NYSE: PFE) has issued a strong response to what it calls...
Basel, Switzerland – October 30, 2025 — Roche Holding AG (SIX: RO, ROG; OTCQX: RHHBY) has successfully completed its...
ABU DHABI, UAE, Oct. 7, 2025 — PureHealth Holding PJSC announced the completion of its €800 million acquisition of...
Hayward, CA – September 9, 2025 – Pulse Biosciences, a pioneer in bioelectric medicine and nanosecond pulsed field ablation...
September 9, 2025 – Basel – In a move set to strengthen its cardiovascular disease portfolio, Novartis announced an...
